We found that IGF2 LOI in prostate cancer is not associated with methylation status in IGF2-DMR0, but associates significantly to hypermethylation of the imprinting control region (IGF2/H19-ICR) located between IGF2 and H19 genes. Here, H19 is linked to prostate carcinoma.